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ABSTRACT 
Chemokines, binding their various G protein-coupled receptors, lead the way for leukocytes in health 
and inflammation. Yet chemokine receptor expression is not limited to leukocytes. Accordingly, 
chemokines are remarkably pleiotropic molecules involved in a range of physiological as well as 
pathological processes. For example, the CXCR3 chemokine receptor is expressed on activated T 
lymphocytes, dendritic cells and natural killer cells, but also fibroblasts and smooth muscle, epithelial 
and endothelial cells. In men, these cells express either CXCR3A, its splice variant CXCR3B or a 
balanced combination of both. The CXCR3 ligands, activating both receptor variants, include CXCL4, 
CXCL4L1, CXCL9, CXCL10 and CXCL11. Upon CXCR3A activation these ELR-negative CXC 
chemokines mediate chemotactic and proliferative responses, for example in leukocytes. In contrast, 
CXCR3B induces anti-proliferative and anti-migratory effects, as exemplified by angiostatic effects on 
endothelial cells. Taken together, the unusual and versatile characteristics of CXCR3 and its ligands 
form the basis for their pertinent involvement in a myriad of diseases. In this review, we discuss the 
presence and function of all CXCR3 ligands in various malignant, angiogenic, infectious, 
inflammatory and other disorders. By extension, we have also elaborated on the potential therapeutic 
applicability of CXCR3 ligand administration or blockade, as well as their additional value as 
predictive or prognostic biomarkers. This review illustrates the multifunctional, intriguing character of 
the various CXCR3-binding chemokines. 
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1. AN INTRODUCTION TO CHEMOKINES 
Originally discovered to be chemotactic cytokines leading the way for leukocytes in health and 
inflammation, the chemokines have now made a name for themselves as pleiotropic molecules 
involved in a range of physiological as well as pathological processes [1, 2]. Most of their effects are 
established by signaling through a set of chemokine receptors, typically G protein-coupled receptors 
(GPCR). Notably, chemokine ligand/receptor binding is both a promiscuous and a redundant 
interaction, meaning that a particular chemokine will show affinity for several chemokine receptors 
and a particular chemokine receptor can be activated by various chemokine ligands, respectively. 
Nevertheless, due to their unique temporal and spatial expression patterns, chemokines often do have 
non-redundant functions in vivo [3]. The biology of chemokines and their receptors is even further 
complicated by the identification of a set of atypical chemokine receptors (ACKR). Highly related to 
the classic G protein-coupled chemokine receptors, ACKR are a smaller subgroup of seven-
transmembrane receptors, which bind chemokines with high affinity, but do not signal through G 
proteins [4]. They were originally considered silent scavenger receptors, however, the majority of 
ACKRs has since been shown to preserve β-arrestin-dependent signaling. Additionally, 
glycosaminoglycans (GAGs) also influence chemokine function, mostly by retaining chemokines at 
the endothelial cell surface and presenting them to passing leukocytes that express corresponding 
chemokine receptors. 
The chemokines themselves are small proteins, not bigger than 8 to 10 kDa. They share a common 
three-dimensional structure defined primarily by four conserved cysteines, two near the amino-
terminal tail of the protein, forming disulfide-bonds with two more internal cysteines. A functional 
distinction is sometimes made between inflammatory and homeostatic chemokines. However, more 
frequently, chemokine classes are subdivided on the basis of their amino acid sequence homology. 
Based on the exact configuration of the amino-terminal cysteine pair, a distinction can be made 
between different subfamilies. The CXC chemokines distinguish themselves from the CC chemokines 
by the inclusion of a single variable amino acid ‘X’ separating those amino-terminally located cysteine 
residues. Together, the CC and CXC subfamilies constitute the majority of chemokines, whereas the C 
and CX3C chemokines represent a limited number of rather unconventional chemokines. Though 
seemingly limited by the constraints of a highly conserved structure, the chemokines are without a 
doubt a diverse superfamily. This certainly also applies to the subfamily of CXC chemokines, which 
has gained extra attention because of its role in the regulation of angiogenesis, the formation of new 
blood vessels, branching of a pre-existing vascular network [5, 6]. Interestingly, a conserved ELR-
motif, consisting of a glutamic acid, leucine and arginine, often precedes the most amino-terminal 
cysteine. The presence of this motif appears crucial in determining the chemokine’s biological 
function as it defines receptor-binding [7]. All ELR-positive CXC chemokines bind the CXCR2 
receptor, expressed on leukocytes, such as neutrophils, and on endothelial cells [8, 9]. Accordingly, 
the ELR-positive CXC chemokines attract neutrophils and promote angiogenesis, respectively. The 
ligands of CXCR1 also contain an ELR-motif and are particularly potent neutrophil chemoattractants. 
On the other hand, CXC chemokines lacking the ELR-motif are unable to bind CXCR2. For example, 
CXCL12/stromal cell-derived factor-1 (SDF-1) alternatively binds CXCR4 and ACKR3/CXCR7, 
receptors to which pro-angiogenic effects have been attributed as well [10]. However, most ELR-
negative CXC chemokines bind the CXCR3 receptor, as do CXCL4/platelet factor-4 (PF-4), 
CXCL4L1/PF-4var, CXCL9/monokine induced by interferon-γ (Mig), CXCL10/interferon-γ-induced 
protein-10 (IP-10) and CXCL11/interferon-inducible T cell α chemoattractant (I-TAC) (Figure 1) [11-
15]. As opposed to CXCR2, this CXCR3 receptor has been ascribed angiostatic properties, specifically 
its splice variant CXCR3B, a variant expressed on endothelial cells [11].  
The CXCR3 ligands thus represent a distinct group of angiostatic chemokines, besides also retaining 
their classic chemotactic potential as they additionally direct migration of CXCR3A-expressing 
lymphocytes to sites of inflammation. Most CXCR3 ligands also bind several GAGs, despite 
considerable differences in affinity among these chemokines [15-17]. They thus compete with various 
angiogenic growth factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast 
growth factor (FGF2), for binding to GAGs on the proteoglycans presented on the endothelial cell 
surface. Consequently, CXCR3 ligands hinder binding of these growth factors to their respective 
signaling receptors [18]. As indicated by recent studies, additionally, direct proteoglycan-mediated 
signaling seems increasingly plausible. Indeed, GAG-binding has been held accountable for effects of 
CXCL4 on monocytes and neutrophils [19-22]. 
2. CXCR3 AND ITS LIGANDS 
2.1. The CXCR3 receptor 
The CXCR3 receptor is a seven-transmembrane GPCR, classified as a CXC-type receptor based on 
the structure of its chemokine ligands. This receptor was indeed originally cloned and characterized as 
an activated T lymphocyte-expressed GPCR selective for ELR-negative CXC chemokines CXCL9 
and CXCL10 [13]. In contrast to other chemokine receptors, the human CXCR3 gene was allocated to 
the X chromosome, in the q13 region [23]. In culture, the percentage of CXCR3-positive T 
lymphocytes has been shown to increase upon interleukin (IL)-2 or IL-2/phytohemagglutinin (PHA) 
stimulation, resulting in up to 95% receptor-expressing cells [23]. T lymphocyte activation 
accordingly induces cell responsiveness to CXCR3 ligands. A heterogeneous group of effector T 
lymphocytes, including CD4+ T helper (Th) cells, CD8+ cytotoxic T lymphocytes (CTL), as well as 
memory T cells, either CD4+ or CD8+,  show highly increased expression of CXCR3 in contrast to 
their naïve precursors [24, 25]. However, among the Th cell population, CXCR3 would particularly 
mark Th1 cells, rather than Th2 or Th17 cells [24, 26]. The transcription factor T-bet, a master switch 
for Th1 and CTL commitment, directly promotes CXCR3 expression [27, 28]. Interestingly, IFN-γ 
signaling, via T-bet, also promotes CXCR3 expression on a subset of Th1-specific regulatory T cells 
[29]. Additionally, natural killer (NK) cells were demonstrated to express CXCR3 [13]. Functional 
expression of CXCR3 was also demonstrated on dendritic cells [15, 30]. CXCR3 ligands have a broad 
spectrum of biological activities, acting on various CXCR3-expressing cell types. Though CXCR3 
expression among immune cells is restricted, with no detectable expression on resting T lymphocytes, 
B lymphocytes, monocytes or granulocytes, a wide variety of non-immune cells have in fact been 
shown to express and display CXCR3 as well, including fibroblasts, endothelial, epithelial and smooth 
muscle cells [31]. These cells do display a variable, cell-dependent expression pattern of different 
human CXCR3 splice variants. Most cells, including leukocytes, predominantly express the originally 
identified CXCR3A. CXCR3A consists of 368 amino acids, encoded by just two exons, separated by a 
single intron, and couples to a Gαi which mediates pro-migratory and proliferative signaling and 
increases intracellular calcium levels [11, 13, 23]. In contrast, endothelial cells exclusively express the 
splice variant CXCR3B, which instead couples to a Gαs subunit, initiating opposing signaling cascades 
[11]. CXCR3B is a 415 amino acid long receptor, generated by alternative splicing at the 5’ end of the 
second exon. Additionally, the inserted sequence comprises an alternative start codon resulting in the 
loss of the four most amino-terminal residues encoded by the first exon, which are replaced by a new 
amino-terminal tail of 51 amino acids. Most CXCR3A-positive cells do exhibit low, parallel 
expression of CXCR3B. Existence of two presumably functionally divergent variants can explain the 
angiostatic effect attributed to CXCR3 ligands. No alternative splicing of the CXCR3 receptor was 
identified in mice, though murine CXCR3 on endothelial cells does exhibit CXCR3-mediated 
angiostatic effects [15]. A cell-dependent signaling mechanism could be involved, establishing 
differential G protein-coupling, independent of CXCR3 splicing. Different intracellular domains of the 
receptor have been shown to determine functional activity, in a ligand-dependent manner [32, 33]. The 
different domains are also of varying importance in establishing distinct, parallel downstream effects. 
However, the determinants of splice variant-dependent differential CXCR3 G protein-coupling remain 
thus far enigmatic. Furthermore, a third human splice variant generated by exon skipping, named 
CXCR3-alt, was later identified [14]. CXCR3-alt consists of only 267 amino acids. This variant shows 
considerable structural and functional dissimilarities attributed to a frame-shift. Only four 
transmembrane domains are conserved and a fifth domain within the alternative carboxy-terminal 
sequence has been postulated [14]. Despite drastically deviating from the classic seven transmembrane 
CXCR3A conformation, CXCR3-alt surprisingly retains affinity for CXCL11, whereas no other 
CXCR3 ligands are bound (Figure 1). Though affinity is lowered, CXCL11 can evoke a CXCR3-alt-
mediated modest calcium increase and chemotactic response [14, 34]. 
Study on altered, chimeric CXCR3/CXCR1 receptors has taught that several distinct extracellular 
domains of human CXCR3A collectively ensure efficient ligand binding and following receptor 
activation, proposing a so-called multi-site model of ligand/receptor interaction [35]. CXCR3’s amino-
terminal tail and first extracellular loop, though dispensable for CXCL9-induced activation, both play 
a more important role in CXCL10- and CXCL11-mediated activation. In fact, sulfation of two tyrosine 
residues in the amino-terminus of CXCR3A was later described to be a necessity for binding and 
activation by all three chemokines [36]. In line with earlier findings, this report did, however, also 
demonstrate CXCL10 and CXCL11 receptor binding to be more sensitive to amino-terminal 
truncation of the receptor compared to CXCL9 [36]. The second extracellular loop of CXCR3A, and 
in particular an arginine at position 216, proved crucial for receptor activation by all interferon (IFN)-
γ-inducible chemokines [35, 36]. Surprisingly though, R216 is no absolute requirement for 
ligand/receptor binding nor CXCR3 internalization. Finally, CXCR3A’s third extracellular loop 
appears necessary for CXCL9 and CXCL10 function [35]. In general, CXCL11 is suggested to be 
more tolerant to substantial changes within the extracellular loops. Accordingly, CXCL11 is indeed 
the only CXCR3 ligand known to induce CXCR3-alt-mediated signaling, as mentioned earlier [14]. 
Note that past research solely focused on the amino acid sequence and structure of splice variant 
CXCR3A, disregarding the binding properties of CXCR3B. The amino-terminal elongation of 
CXCR3B and the associated shift in affinity towards different CXCR3 ligands, can be reconciled 
though with the postulated multi-site model and the reported impact of amino-terminal changes on 
ligand binding. Beyond the altered 51 amino acid long amino-terminal tail, both splice variants are 
identical. Presumably, other findings on the structure and function of CXCR3A can thus be extended 
to CXCR3B.  
Among the CXCR3-binding chemokines, two groups clearly can be distinguished based on their 
overall biology and biochemistry (Table 1). On one hand, the IFN-γ-inducible chemokines CXCL9, 
CXCL10 and CXCL11 constitute the traditional CXCR3 ligands. The platelet-derived chemokines 
CXCL4 and CXCL4L1, on the other hand, were only later recognized to bind both CXCR3A and 
CXCR3B as well and represent a distinct pair of CXCR3 ligands. 
2.2. IFN-γ-inducible CXCR3 ligands 
Three ELR-negative CXC chemokines, CXCL9, CXCL10 and CXCL11, can together be referred to as 
the IFN-γ-inducible CXCR3 ligands [12, 37, 38]. Though they share a common inflammatory 
function, they do collectively gain fine control over leukocyte trafficking [3]. The mature IFN-γ-
inducible chemokines display about 40% amino acid sequence identity between one another (Figure 
2). However, the expression of CXCL9, CXCL10 and CXCL11 is regulated by unique promoters 
establishing distinct temporal and spatial expression patterns (Table 1). They are indeed differentially 
expressed by various cell types, induced by specific cytokines and Toll-like receptor (TLR) ligands or 
by combinations thereof [3, 39-41]. Furthermore, these chemokines all exhibit different receptor 
binding characteristics, different efficacy as well as potency. Generally, CXCL11 has the highest 
affinity for CXCR3A, whereas CXCL9 has the lowest. CXCL11 is also the most potent of the IFN-γ-
inducible CXCR3 ligands, as measured by both mobilization of intracellular calcium and chemotactic 
response in CXCR3A-expressing cells [12]. However, CXCL10 expression appears more receptive to 
a range of different stimuli and has been associated accordingly with a multitude of physiological as 
well as pathological conditions [3]. CXCL10 is the most thoroughly investigated CXCR3 ligand and 
could be suggested a prototypical example of the IFN-γ-inducible chemokines. 
2.3. Platelet-derived CXCR3 ligands 
The mature chemokines CXCL4 and CXCL4L1 both show 37% sequence identity with the IFN-γ-
inducible CXCR3 ligand CXCL10 (Figure 2). However, among themselves, these non-allelic variants 
show a striking 96% amino acid identity. CXCL4L1 is a non-allelic variant of CXCL4 which arose 
from a gene duplication unique to primates [42]. Only three amino acid substitutions near the carboxy-
terminal end distinguish the mature chemokines. Yet this subtle difference suffices to alter the 
chemokine’s three-dimensional structure drastically, reducing CXCL4L1’s affinity for GAGs and 
resulting increased angiostatic potential of the variant CXCL4L1 [42, 43]. 
On the other hand, CXCL4 and CXCL4L1 clearly differ from the other CXCR3 ligands firstly based 
on their affinity for CXCR3A and CXCR3B, but also because their expression is not classically 
induced by IFN-γ. Even more, they are primarily released by activated platelets, therefore coined as 
the platelet-derived CXCR3 ligands [43, 44]. 
 
3. CXCR3 LIGANDS IN DISEASE 
Given their pleiotropic nature, CXCR3 ligands play their part in a myriad of diseases. Involvement of 
all CXCR3 ligands has been observed in various angiogenesis-related pathologies as well as 
immunological disorders, the latter being mostly related to autoimmunity or infection [45, 46]. Here 
we discuss a varied and extensive, yet not exhaustive, repertoire of diseases having been associated 
with CXCL4, CXCL4L1, CXCL9, CXCL10 or CXCL11. The CXCR3 ligands are indeed 
characterized by their unique position at the crossroad of immunity and angiogenesis and accordingly 
play an exceptional role in health, disease and therapy. 
3.1. Carcinoma and sarcoma 
The CXCR3 ligands have been associated with many diseases, some new and still poorly understood, 
some already the subject of a long line of research. Their association with the pathogenesis and 
prognosis of cancer definitely belongs to the latter. The immunoangiostatic CXCR3 ligands are 
established players in numerous carcinomas and sarcomas [47]. Angiogenesis is indeed a critical 
process providing the expanding malignant tissue with oxygen and nutrients and clearing it of 
metabolic waste products [48, 49]. While these newly formed blood vessels allow successful tumor 
growth, the lymphatic vasculature will serve as an additional escape route for metastatic tumor cells, 
especially in later stages of tumor progression [50]. Recent reports reveal that CXCR3 ligands, 
specifically the platelet factors, are effective inhibitors of lymphangiogenesis as well [51] and hence 
support the belief that these chemokines are interesting, multifunctional anti-tumoral agents (Figure 3). 
Furthermore, immunity also plays an ambiguous role. Generally, the tumor is believed to corrupt the 
immune system and suppress any anti-tumoral reactivity, possibly even attracting immune cells that 
will further promote tumor vascularization [52]. In contrast, immune polarization of the tumor 
microenvironment could potentially stimulate the anti-tumoral immune response, attracting CXCR3A-
expressing, anti-tumoral CTLs, activated Th1 lymphocytes and NK cells [53]. It is no wonder that 
several chemokines, being immunological players attributed both angiogenic and angiostatic 
properties, also play their part in tumor development [45]. An abundance of studies have reported 
overexpression or absence of CXCR3 ligands, especially CXCL10, in cancer patients [47, 54]. Despite 
a broad understanding of their potential anti-tumoral activity, the associated clinical significance often 
remains enigmatic. The impact of CXCR3 ligands on both tumor and tumor microenvironment is 
further complicated by some tumors’ ability to express the CXCR3 receptor. CXCR3 expression was 
illustrated in many different cancers, formerly without distinguishing CXCR3A from CXCR3B [55-
58]. Given tumoral Gαi-coupled CXCR3A surface expression, CXCR3 ligands will stimulate tumor 
cell migration and proliferation thereby promoting tumor invasiveness (Figure 4) [59]. CXCL4 and 
CXCL10 were accordingly reported to promote the metastatic potential of human, predominantly 
CXCR3A-expressing, prostate cancer cells in vitro [59]. In several other cancers, tumoral expression 
of CXCR3 was also associated with lymph node invasion or generally poor prognosis [60-62]. While 
mostly considered anti-tumoral agents, CXCR3 ligands can thus also have a detrimental, pro-tumoral 
effect under certain conditions. These findings require careful consideration to assure safe and 
efficient future therapeutic applicability. The impact of individual differences in tumoral CXCR3A 
and CXCR3B expression demands a personalized approach. 
3.2. Leukemia, lymphoma and myeloma 
Leukemia, lymphoma and myeloma, collectively referred to as hematopoietic malignancies, represent 
a rather unique set of cancers affecting leukocytes and their progenitors. All three diseases can be 
further divided into subclasses. As for leukemia, a distinction is made between acute or chronic, and 
lymphoid or myeloid disorders. Interestingly, the CXCR3 receptor and its ligands have been discussed 
in the context of all four major subtypes. In chronic lymphocytic leukemia (CLL), the CXCR3-
signaling axis has mostly been linked to trafficking of CLL malignant B cells, which consistently 
express functionally active CXCR3, unlike B cells isolated from healthy subjects [63, 64]. CLL cells 
themselves were also frequently observed to co-express CXCL9 [64]. Furthermore, CXCL9, CXCL10 
and CXCL11 were identified as part of an outcome-correlated cluster of cytokines, differentially 
expressed in CLL, with elevated serum levels serving as an indication of aggressive disease [65]. The 
cluster additionally consisted of CCL3, CCL4, CCL19, IL-5, IL-12 and IFN-γ. On the other hand, low 
levels of CXCR3 expression by CLL B cells have previously been reported to predict a poor outcome 
and shorter survival as well [66]. In acute lymphoblastic leukemia (ALL), CXCL10 produced by 
monocytes in the vicinity of malignant blasts was hypothesized to have a direct pro-tumoral effect 
promoting tumor cell invasiveness [67]. CXCL10 serum levels in ALL patients were also proven to be 
increased compared to controls [68]. In contrast, decreased serum levels of another CXCR3 ligand, 
CXCL4, were discovered to characterize pediatric ALL [69]. Remarkably, involvement of CXCL4 in 
the oncogenesis of ALL was strongly supported by the identification of a translocation shared among a 
subset of ALL patients, with a breakpoint in 4q21, distal to the CXCL4 gene [70, 71]. Similarly, in 
acute myeloid leukemia (AML) CXCL4 serum levels were decreased as well, yet progressed in 
relation to therapy responsiveness, with increasing concentrations indicating AML remission [72, 73]. 
On the other hand, AML cells often constitutively produce CXCL10, with wide variations between 
patients potentially reflecting disease status [74]. Considering chronic myeloid leukemia (CML), a 
fourth leukemic subtype, CXCL10 mRNA levels were just recently reported to be upregulated in 
peripheral blood mononuclear cells isolated from CML patients, linking CXCR3 ligands to the 
pathogenesis of CML as well [75]. Dysregulation of CXCL10 gene expression has in fact been 
associated with several recurrent chromosomal translocations identified in different leukemic 
pathologies [76]. 
Hodgkin’s lymphoma tissue also generally presents higher levels of CXCL9 and CXCL10 expression, 
though major differences are noted among different subtypes with predominant expression in Epstein-
Barr virus (EBV)-positive cases and cases associated with mixed cellularity [77, 78]. Both chemokines 
were shown to be expressed by malignant cells as well as surrounding cells such as macrophages, 
lymphocytes and endothelial cells. This overexpression of both CXCL9 and CXCL10 has actually 
been associated with tumor tissue necrosis and vascular damage, consistent though with their general 
anti-tumoral activity. This duality was also illustrated in non-Hodgkin lymphoma, with on one hand 
reports of CXCL9 expression in B-cell lymphomas facilitating dissemination of CXCR3-positive 
malignant B cells [79-81] and on the other hand the suggestion that CXCL9 and CXCL10 are in fact 
associated with a protective immune response successfully targeting B cell cancer, comparable to their 
anti-tumoral activity reported in solid tumors [82]. 
Finally, for most multiple myeloma (MM) cases, freshly purified MM plasma cells have been shown 
to express CXCR3, making them responsive to chemokines like CXCL9, CXCL10 and CXCL11 [83]. 
Remarkably, myeloma cells express both CXCR3 splice variants, at varying ratios and in a cell cycle-
dependent manner, potentially explaining the reported anti-proliferative effect of CXCL10 [84, 85]. As 
for CXCL4, shown to induce apoptosis of myeloma cells, this platelet factor was identified as tumor 
suppressor gene commonly silenced in MM as a consequence of promoter hypermethylation [86, 87]. 
In conclusion, most hematological cancers have, in one way or another, been linked to CXCR3 ligand 
expression. However, seldom their exact pathological or oncogenic function is really understood. This 
is a domain that requires further research, especially considering the prospects for leukemia patients 
and the shortcomings of current treatments. CXCL4 in particular appears to present promising new 
therapeutic opportunities as this chemokine may also serve to protect normal hematopoietic cells from 
the toxicity of chemotherapeutics, without affecting the viability of cancerous cells [88]. 
3.3. Inflammatory arthritis 
Over the years, CXCR3 ligands and their function in autoimmune diseases such as rheumatoid arthritis 
(RA) have been extensively reported and reviewed [89]. In RA patients, recruitment of CXCR3-
expressing T cells and mast cells to the inflamed synovium was indeed related to a preferential 
upregulation of CXCL9 and CXCL10 expression in the synovial fluid and tissue compared to 
chemokine levels in traumatic arthritis or osteoarthritis [90, 91]. This association was later also 
extended to enhanced CXCL4 expression concurrently with synovial inflammation in RA [92]. 
Elevated CXCL4 plasma levels have also been observed in a subset of RA patients, specifically 
concurrent with the formation of active vascular lesions [93]. Plasma CXCL4 concentrations might 
indeed prove to be a useful marker of endothelial injuries in rheumatic disorders [93]. Furthermore, 
synovial CXCL10 expression was also found to be increased in juvenile idiopathic arthritis [94]. Also 
in septic arthritis, inflammatory induction of CXCL9 and CXCL11 has been reported [41]. However, 
clearly distinguishing itself from other IFN-γ-inducible chemokines, evidence regarding increased 
secretion of CXCL11 in RA remains controversial [39, 95]. High synovial expression of CXCL11 in a 
particular subpopulation of RA patients has, however, been identified as an indication of poor therapy 
responsiveness to adalimumab, a TNF-antagonist [96]. 
3.4. Inflammatory bowel disease 
The CXCR3 axis has been implicated in the pathogenesis of both Crohn’s disease and ulcerative 
colitis, two chronic gastrointestinal disorders collectively referred to as inflammatory bowel disease 
(IBD) [97, 98].  Raised plasma levels of CXCL4 were observed in Crohn’s disease already in 1987 
[99] and were furthermore correlated with IBD clinical activity [100]. Serum CXCL4 has more 
recently also been identified as a general biomarker for IBD in a proteomic serum profiling pilot study 
[101]. Though serum CXCL10 levels were also suggested to reflect disease activity in ulcerative 
colitis [102], expression of IFN-γ-inducible CXCR3 ligands has mostly been found to be increased 
locally, driving mucosal accumulation of inflammatory cells [97, 103, 104]. Accordingly, it has been 
suggested that these IFN-γ-inducible chemokines could contribute to the progression of IBD and 
worsen the associated inflamed state of the gastrointestinal tract [104, 105]. Involvement of the 
CXCR3 axis genes was supported by the report of a persistent overexpression of CXCL9, CXCL10, 
CXCL11 and CXCR3 in the inflamed colonic tissue of pediatric IBD patients [106]. A particular 
CXCL11 genotype, namely the rs6817952 A allele situated in intron 1, even proved to be a risk factor 
for both ulcerative colitis and pediatric Crohn’s disease [106]. In a similar report, a CXCL9 
polymorphism, 77147452G>A, showed an inverse association with pediatric Crohn’s disease [107]. 
These genetic association studies underline the importance of the CXCR3 receptor and its ligands in 
the pathogenesis of IBD and could inspire new therapeutic strategies. 
3.5. Diabetes 
As an autoimmune disease, type 1 diabetes has repeatedly been associated with elevated levels of the 
typical Th1 chemokine CXCL10, a correlation unveiled by Shimada and colleagues and reassessed 
earlier this year by the group of Antonelli et al. [108, 109]. It is further hypothesized that CXCL10 
serum levels would increase especially during the early Th1-driven stages of disease [110, 111]. 
However, there is also a minority of studies contesting this positive association between serum 
CXCL10 and type 1 diabetes [112, 113]. Nevertheless, generally it is accepted that hyperglycemic and 
inflammatory CXCL10 production plays an important role in the pathogenesis of type 1 diabetes [114-
116]. While monocytes are an important source of the chemokine, pancreatic beta cells in patient 
biopsies were actually shown to express and secrete CXCL10 themselves as well, contributing to 
autoreactive T cell islet infiltration and consequent beta cell destruction [117-119]. Potentially, beta 
cell-secreted CXCL9 may also attract CXCR3-expressing T cells [120]. Through TLR4 signaling, 
CXCL10 has even been described to interfere directly with pancreatic beta cell proliferation and 
viability, an effect originally assumed to be mediated by CXCR3 expressed on pancreatic beta cells 
[121-123]. Regardless of the controversy concerning involvement of CXCR3 itself, this direct effect 
on pancreatic beta cell numbers implicates CXCL10 not only in the progression of type 1 but also of 
type 2 diabetes, as a lack of proliferation prevents beta cells from meeting increased insulin demands, 
for example in obese or pregnant patients [122]. Accordingly, the latter study indeed showed that in 
type 2 diabetes patients, unlike healthy controls, pancreatic beta cells also express and secrete 
CXCL10.    
Though not always clear-cut, several studies have investigated the association between platelet 
activation and coagulation factors on one hand and diabetes on the other. This also led to the 
observation that diabetic patients present increased CXCL4 plasma levels, presumably related to 
enhanced platelet activation [124, 125]. Like most CXCR3 ligands, CXCL4 has been studied 
regarding its involvement in complications of diabetes, such as proliferative diabetic retinopathy 
(PDR) [125, 126]. Characterized by distorted, pathological neovascularisation of the retina, several 
angiogenic factors have been shown to have a causative link to this pathology. But the distorted 
angiogenic balance in the diabetic eye also affects the angiostatic proteins involved, showing a 
counterintuitive upregulation of inhibitors of angiogenesis such as the CXCR3 ligands [127]. 
Chemokine concentrations measured in the vitreous fluid of patients correlate to clinical PDR 
manifestation. For example, vitreous CXCL9 levels have been shown to be elevated in patients with 
active PDR, but not in patients with inactive PDR [126]. A causal role for the CXCR3 ligands in this 
severe complication in diabetes patients may remain enigmatic, but their potential as disease markers 
is apparent as is their potential therapeutic applicability. 
3.6. Systemic sclerosis  
Proteome-wide analysis recently revealed circulating and dermal plasmacytoid dendritic cells isolated 
from systemic sclerosis (SSc) patients to display markedly increased CXCL4 expression [128]. This 
study also confirmed plasma CXCL4 levels to be elevated, as had been previously described [129, 
130]. More importantly, plasma levels of CXCL4 correlated with disease severity, specifically the 
presence and progression of complications such as pulmonary arterial hypertension and lung or skin 
fibrosis [128]. Increased CXCL4 levels had previously been measured in the bronchoalveolar lavage 
fluid of SSc patients [131]. Similarly, serum concentrations of the IFN-γ-inducible CXCR3 ligand 
CXCL10 appear indicative of disease activity [132]. Increased serum CXCL10 levels also correlate 
with the manifestation of pulmonary arterial hypertension [133]. In general, increased serum levels of 
CXCL9 and CXCL10 have been described consistently in SSc patients [134-136]. In contrast, low 
concentrations of CXCL11 in the lung have been associated with a greater likelihood of pulmonary 
function decline [137]. 
3.7. Transplant rejection 
As potent T cell-chemoattractants, CXCL9 and CXCL10 have been demonstrated repeatedly to play a 
central role in the immune response against transplant tissue, leading to allograft rejection [138, 139], 
despite a few reports opposing involvement of the CXCR3 axis [140]. Regulating immune cell 
differentiation, migration and proliferation, local chemokine levels indeed closely relate to the host 
immune status, both pre- and post-transplantation [141-144]. Upregulation of CXCL10 expression, 
potentially serving as a biomarker predicting allograft failure, is indeed reflected by chemokine 
concentrations in serum and urine [139, 145], as is CXCL9 expression according to some studies 
[146]. These findings have been reported in various organs, including the transplanted kidney, lung, 
heart and liver [147-153]. Similar to CXCL9 and CXCL10, the third IFN-γ-inducible chemokine, 
CXCL11, has been observed to be upregulated in a number of transplant studies [151, 152, 154, 155]. 
As measured in endomyocardial biopsies, a persistent elevation in CXCL10 and CXCL11 mRNA 
expression was found to correlate with the occurrence of transplant vasculopathy, a severe 
complication among heart transplant recipients causing allograft ischemia [156]. 
A murine study also associated CXCL4 with allograft rejection in the context of cardiac 
transplantation. However, CXCL4 was actually considered a negative regulator of T cell reactivity to 
cardiac transplantation, by limiting Th17 differentiation [157]. 
CXCR3-binding chemokine levels have also been associated with patient prognosis after bone marrow 
transplantation, more specifically in the context of graft-versus-host-disease (GVHD), a complication 
in which transplanted donor cells regard the host tissue as foreign. The importance of CXCL10 in the 
pathogenesis of this disease was first recognized in acute GVHD, characterized by epidermal CXCL10 
expression and recruitment of CXCR3-positive T cells to the skin [158]. Serum levels of this 
chemokine were significantly increased during acute GVHD. Furthermore, serum levels of all three 
IFN-γ-inducible CXCR3 ligands, CXCL9, CXCL10 and CXCL11, also correlated to episodes of 
chronic GVHD of the skin [159]. Correspondingly, during ocular manifestation of chronic GVHD, 
increased expression of CXCL9 and CXCL10 has been observed within the conjunctiva [160]. These 
observations thus suggest a central role for the CXCR3 ligands in the pathogenesis of both acute and 
chronic GVHD. 
3.8. Malaria 
The role of platelets in malaria, and with it a potential involvement of the platelet-specific protein 
CXCL4, has been recognized early on [161, 162]. In 1983, Essien and Ebhota described elevated 
CXCL4 plasma levels in patients upon acute Plasmodium falciparum infection [163]. On the other 
hand, the IFN-γ-inducible CXCR3 ligands were later implicated in the pathogenesis of malaria as well. 
Most importantly, the CXCR3 ligands have been associated with the occurrence of cerebral malaria 
(CM), a lethal complication of Plasmodium falciparum infection in humans [164, 165]. Aspiring to 
identify prognostic markers that may predict CM severity and hopefully improve intervention, 
CXCL10 and CXCL4, in contrast to CXCL9 or CXCL11, were found to be exceptional serum markers 
associated with CM mortality [166, 167]. Following up on the potential value of CXCL10 in 
predicting CM associated mortality, a specific CXCL10 gene promoter polymorphism -1447A>G, 
associated with higher plasma CXCL10 levels, was identified as a genetic risk factor predicting 
clinical severity of malaria and susceptibility to CM [168]. The hypothesized key role for CXCL10 in 
cerebral malaria was further supported by preclinical data illustrating that this chemokine promotes 
accumulation of CXCR3-positive T lymphocytes in the brain, an essential part of the pathogenesis of 
CM [165, 169-171]. In parallel to CXCL10, a prominent role for CXCL4 in the pathogenesis of fatal 
CM was suggested as well [167]. Murine CXCL4 contributed to the vascular inflammation, driving 
both T cell and monocyte trafficking, which consequently leads to cerebral vascular injury typical of 
the development of experimental CM [172, 173]. Despite the lack of an identified correlation in 
patients, preclinical studies have also connected CXCL9 to this severe complication [174-177]. 
Moreover, in murine models of CM, CXCR3 expression or in contrast lack thereof has been associated 
with susceptibility to or protection against fatal murine CM, respectively [165, 169, 170, 176]. 
Protection goes hand in hand with a reduction of T lymphocyte recruitment in response to the IFN-γ-
inducible CXCR3 ligands excessively expressed in the brain [170]. Neutralisation of CXCL10 in mice 
inhibits the recruitment of T cells from the spleen to the brain, thereby preventing cerebral 
inflammation and improving parasite clearance in the spleen [171]. In contrast, the protective, 
antimalarial effect of CXCL4 can be traced back to its remarkable quality to bind the Duffy-antigen 
receptor for chemokines (ACKR1/DARC) expressed on erythrocytes [178-180]. Activated platelets, 
bound to malaria-infected red blood cells, will locally release high concentrations of CXCL4, which in 
turn binds DARC leading to intraerythrocytic parasite-killing [179, 181, 182]. 
3.9. Acquired Immune Deficiency Syndrome 
Serving as co-receptors for cell-specific human immunodeficiency virus (HIV) entry, CCR5 and 
CXCR4, as well as several other chemokine receptors, have been identified as critical pawns in HIV 
infection and pathogenesis, eventually leading to acquired immune deficiency syndrome (AIDS) [183, 
184]. Though it was demonstrated that CXCR3 is also a potential co-receptor, given its marginal co-
receptor efficiency, clinically CXCR3 is unlikely to take significant part in the process of HIV 
infection [185]. On the other hand, the receptor and its ligands do play a role in the progression of this 
disease, even though it may not yet be entirely clear what that role entails. 
Firstly, plasma levels of CXCL10 were recently suggested as a marker to predict viral load [186, 187]. 
Furthermore, CXCL10 has been detected in the cerebrospinal fluid (CSF) of HIV-1-infected patients, 
driving the accumulation of activated T cells and accordingly contributing to the occurrence of HIV-
associated disorders of the central nervous system [188-190]. It was indeed repeatedly shown that a 
variety of cells, including dendritic cells, macrophages and lymphocytes but also astrocytes and 
microglia, can express significant amounts of CXCL9, CXCL10 and CXCL11 following HIV-
infection [191-195]. Notably, CXCL10 was also identified as a direct neurotoxic factor [196, 197]. 
Most importantly, recruitment of susceptible CXCR3-expressing T cells to virus-infected 
macrophages, dendritic cells and lymph nodes is favored, ensuring ongoing propagation of the virus in 
newly supplied target cells and inflicting the general immunopathology of AIDS [192, 198]. 
Interestingly, the CXCR3 ligands also have a more direct impact on HIV infection as CXCL9, 
CXCL10 and CXCL11 were all shown to stimulate virus replication in a CXCR3-dependent manner 
[199]. 
Similar to the other CXCR3 ligands, CXCL4 also affects the pathogenesis of HIV. Remarkably, 
CXCL4 is believed to interfere specifically with the earliest events in the viral infectious cycle and 
would actually be a key player in the first line defense against HIV-1 [200, 201]. Activated platelets 
inhibit host cell entry by HIV through the release of CXCL4, which behaves as a broad-spectrum 
inhibitor, directly interacting with the major viral envelope glycoprotein, gp120, and thereby 
suppressing attachment and entry [200]. Unlike the other CXCR3 ligands, CXCL4 thus would be 
ascribed a protective role, supported by an inverse correlation between CXCL4 serum levels in HIV-1-
infected patients and the clinical stage of their disease [200]. 
On a side note, CXCR3 ligands also seem to be involved in opportunistic infections manifesting in 
HIV-positive patients. In this context, the IFN-γ-inducible chemokines, especially CXCL10, have 
been linked to hepatitis C [202-205], tuberculosis [206, 207] and even malaria [208]. 
3.10. Hepatitis 
In general, CXCR3-binding chemokines have been ascribed direct antimicrobial activity, mostly 
directed towards bacteria and malaria parasites [178, 182, 209, 210]. However their involvement in 
leukocyte recruitment and differentiation places the CXCR3 ligands at the front line of the host 
defense against different infectious diseases, including viral infections of the central nervous system 
[211, 212]. A link was also established between the IFN-γ-inducible chemokines and viral hepatitis, 
mostly hepatitis C [213]. However, the hepatitis C virus (HCV) can modulate the chemokine system, 
upregulating inflammatory chemokines yet subverting a specific immune response, postulated to result 
in the establishment of chronic low-grade inflammation and an impaired viral clearance [213, 214]. 
Both CXCL9 and CXCL10 have been reported to facilitate accumulation of T lymphocytes in the 
infected liver leading to patchy lobular inflammation, an important predictor of progressive liver 
injury [215-217]. Elevated CXCL10 plasma levels indeed mark hepatitis C patients with advanced 
fibrosis, whereas CXCL9 levels according to some studies mostly associate with advanced 
inflammation [218]. It has even been reported that CXCL9 may exert antifibrotic effects [219]. 
Additionally, Sahin and colleagues recently suggested CXCL10 has a direct pro-apoptotic effect on 
hepatocytes as well, potentially contributing to CXCL10-associated liver injury [220]. 
CXCL11 is also expressed by hepatocytes in chronic hepatitis C and promotes recruitment of pro-
inflammatory T cells and subsequent portal and lobular inflammation [221]. Its intrahepatic expression 
may be mildly elevated in chronic hepatitis C patients with higher necroinflammation and fibrosis 
[222]. 
Finally, Zaldivar and colleagues revealed that patients with advanced HCV-induced fibrosis present 
increased CXCL4 serum concentrations and intrahepatic CXCL4 mRNA levels [223]. Also in non-
viral, alcoholic hepatitis, increased expression of CXCL4 and CXCL10 in patient liver biopsies was 
reported [224]. Similarly, elevated serum concentrations and intrahepatic expression levels of CXCL9 
and CXCL10 were shown to be positively associated with severity of liver fibrosis in chronic liver 
diseases of different etiologies, viral or otherwise [225]. 
3.11. Atherosclerosis 
The initiation and progression of atherosclerosis, an arterial narrowing caused by the formation of 
progressive and degenerative plaques, is fundamentally intertwined with the chemoattraction and 
modulation of immune cells, most importantly monocytes and lymphocytes. Activated T lymphocytes 
accumulate in the atheroma early on, recruited at least in part by locally expressed CXCL9, CXCL10 
and CXCL11 [226]. Different studies have indeed highlighted the effect of these chemokines on 
lesional T cell infiltration and as such on the consequent progression of atherosclerotic plaques [227-
229]. On the other hand, CXCL4 differs from the others in that this chemokine mostly retains 
peripheral monocytes at the lesion site, where this proatherogenic chemokine is released at high 
concentrations following platelet activation [230]. Heterodimerization of CXCL4 with another platelet 
chemokine, CCL5/RANTES, even further enhances monocyte recruitment [231]. As reviewed by 
Aidoudi and Bikfalvi, many diverse regulatory mechanisms are involved in the achieved impact of 
CXCL4 on the progression of atherosclerosis [232]. CXCL4 instigates local monocyte differentiation 
to macrophages and controls their polarization [22, 233]. Remarkably, this platelet factor also 
modulates the low-density lipoprotein (LDL) cholesterol metabolism by inhibiting degradation of the 
LDL-receptor. CXCL4 simultaneously prevents native LDL to bind to its receptor, but selectively 
promotes the macrophage’s uptake and following esterification of oxidized LDL, a crucial step in the 
development of foam cells which form the basis for future atherosclerotic plaques [232-234]. 
Accordingly, lesional CXCL4 deposition is shown to correlate with the clinical manifestation of 
atherosclerosis [235]. This enforces the hypothesis that CXCR3 ligands, though each via specific 
mechanisms, collectively contribute to the progression of atherosclerosis to a symptomatic disease 
[227, 235, 236]. 
3.12. Alzheimer’s disease 
Alzheimer’s disease (AD) is a neurodegenerative disorder in which deposition of neurotoxic β-
amyloid peptides, forming senile plaques, as well as formation of neurofibrillary tangles cause brain 
lesions leading to severe dementia [237]. Typically, AD patients also present with neuroinflammation. 
The physiological role of chemokines and their receptors in the brain has been established before, but 
even more so are they considered to be associated with the pathogenesis of various neurological 
diseases, including AD [238]. Reactive astrocytes in AD were reported to display elevated CXCL10 
expression and CXCL10- as well as CXCL9-induced signaling was confirmed in CXCR3-expressing 
neurons [239]. These findings were corroborated by reports of CXCL10-mediated calcium 
dysregulation and apoptosis in neurons, and thus neurotoxicity [240]. CXCL10 has also been reported 
to regulate migration of astrocytes themselves thereby promoting astrocyte aggregation around senile 
plaques [241]. Furthermore, CXCL10 concentrations in the CSF, as opposed to serum levels, were 
increased in AD patients, specifically during the early phase of disease, characterized by a mild 
cognitive decline and typically associated with more pronounced inflammatory events [242-244]. 
Increased CXCL10 expression was also observed in the brain of transgenic AD mice in which 
colocalization of β-amyloid and CXCL10 immunoreactivity was illustrated [245]. Taken together, 
evidence strongly suggests a causative role for CXCL10 in the pathogenesis of AD, possibly 
extendable to other neurodegenerative disorders. 
On the other hand, involvement of CXCL9 remains controversial as opposing reports regarding 
CXCL9 plasma levels in AD patients have been published [246, 247]. Additionally, considering the 
role of platelet activation, CXCL4 has also been suggested to support chronic inflammation in AD 
patients, though this hypothesis remains to be further investigated [248, 249]. 
3.13. Thrombocytopenia 
Most of the CXCR3 ligands display a remarkable affinity for glycosaminoglycans, though none as 
outspoken as CXCL4. Glycosaminoglycans are believed to act as co-receptors for CXCR3 ligands, 
particularly in the process of leukocyte rolling and efficient tissue intravasation [250]. Yet the 
formation of CXCL4/heparin complexes upon administration of heparin as an anti-coagulant can also 
lead to a rare and paradoxical complication as the odd patient will develop antibodies against a 
CXCL4/heparin-epitope in the vicinity of the platelet surface [251]. This complication is referred to as 
heparin-induced thrombocytopenia (HIT). Patients developing HIT are at risk of venous as well as 
arterial thrombosis, despite low platelet counts [252].  
4. CXCR3 LIGANDS IN THERAPY 
A great range of pathologies, mostly characterized by inflammation or vascular effects, have clearly 
been associated with changes in the expression levels of CXCR3 and CXCR3-binding chemokines 
(summarized in Table 2). More importantly, often the expression of these chemokine ligands and 
receptor correlates to pathogenesis, disease progression and prognosis or, under particular conditions, 
could reflect a failing compensation mechanism. Insight into CXCR3 biology has consequently 
inspired the development of new therapeutics and continues to highlight new avenues worth exploring. 
Generally speaking, most CXCR3 axis-based therapies can be assigned to either the anti-inflammatory 
approach, by preventing CXCR3 activation, or an angiostatic approach, through the administration of 
exogenous CXCR3 ligands or peptides derived thereof. Possibly, this CXCR3 activation may also 
promote effective immune responses. 
4.1. CXCR3 ligands as angiostatic and anti-tumoral therapeutics 
Cancer is a prototypical angiogenic disorder in which neovascularization plays a crucial role in tumor 
progression and thus offers a promising therapeutic target. The angiostatic chemokines may represent 
an opportunity in the optimization of current anti-angiogenic regimes. Earlier in this review, we have 
elaborated on the anti-tumoral characteristics of CXCR3-binding chemokines, granted the malignant 
cells themselves do not express the CXCR3A splice variant. Though currently clinical use has not yet 
been tested, a wide selection of publications has discussed the benefits of CXCR3-based anti-tumoral 
strategies in various preclinical mouse models (Table 3).  
Numerous experimental approaches have been described: different cancer models, combinations with 
other therapeutics, and administration strategies ranging from intratumoral chemokine injections to 
treatment with viral vectors [253]. Moreover, use of the CXCR3 ligands is also being fine-tuned by 
testing the impact of different alterations on their anti-tumoral activity. Carboxy-terminal peptides 
derived from the platelet factors [254, 255], even a chimeric chemokine integrating aspects of both 
CXCL10 and CXCL11 [256] or synthetic peptides such as anginex, which contains structural elements 
of CXCL4, CXCL8 as well as bactericidal permeability-increasing protein [257], have been tested to 
optimize therapeutic efficacy (not included in table). Commonly, despite some exceptions, 
administration of CXCR3 ligands or derived preparations has shown innovative therapeutic benefit, 
holding promise for the future of anti-angiogenic cancer treatments. 
Besides their application in cancer, administration of angiostatic chemokines like the CXCR3 ligands 
may also benefit patients suffering from many other angiogenic disorders, for example pathological 
ocular neovascularization in diabetic retinopathy. 
4.2. CXCR3 ligands as targets in anti-inflammatory therapy 
As IFN-γ-inducible, T cell-attracting chemokines, CXCL9, CXCL10 and CXCL11 most definitely 
play an important role in host immunity, yet they can also instigate endless amplification loops leading 
the way for excessive, detrimental immune responses [89]. Inflammatory disorders could benefit from 
anti-inflammatory agents inhibiting CXCR3 ligands and thereby breaking the cycle. Human 
monoclonal antibodies against CXCL10 have been developed for clinical use (MDX-1100/BMS-
936557 and NI-0801; ClinicalTrials.gov). Thus far, use of the anti-CXCL10 antibody BMS-936557 
has been examined in the treatment of IBD and RA patients and phase II trials have been completed 
reporting clinical efficacy in patients who previously responded inadequately to methotrexate [258, 
259]. Treatment was generally well tolerated in both patient populations. Studies in cirrhosis patients 
are also ongoing, with a phase II trial just recently having been finalized (Study ID NCT01430429; 
ClinicalTrails.gov). CXCL10 could be considered the more clinically prominent of inflammatory 
CXCR3 ligands and therefore an obvious therapeutic target, however other chemokines of this group 
represent valuable alternatives. For example, CXCL4 takes on an interesting role in atherosclerosis 
and has been proposed as a promising therapeutic target as well [260, 261]. Other inflammatory 
disorders that may benefit from CXCR3 ligand blockade include type 1 diabetes, multiple sclerosis, 
allograft rejection, etc. [262, 263]. 
4.3. CXCR3 ligands as prognostic and predictive biomarkers 
Finally, in many diseases, CXCR3 ligands provide an accessible readout for patient diagnosis, 
prognosis or therapy responsiveness. Prognostic significance of CXCL4L1 serum concentrations, for 
example, was evidenced in stable coronary artery disease, in that lower CXCL4L1 levels were 
associated with a higher event rate and overall worse outcome [264]. In both Crohn’s disease and RA, 
high plasma levels of CXCL4 have been shown to predict non-responsiveness to anti-TNFα antibody 
(infliximab) therapy [265, 266]. CXCR3 ligands have also been identified as crucial instigators of 
transplant inflammation and following allograft rejection [138]. Their expression, both pre- and post-
transplantation, is a reflection of the patient’s immune status. Urinary CXCL9 and CXCL10 have 
accordingly been described as useful, non-invasive biomarkers to predict or diagnose allograft 
rejection before overt clinical manifestation or irreversible graft injury [139, 146]. In the context of 
HCV, an association was noted between, on one hand, either intrahepatic or plasma levels of CXCL10 
and, on the other hand, the patient’s overall response to pegylated IFN-α2 and ribavirin combination 
therapy [267, 268]. Low baseline levels of CXCL10 proved to indicate a better outcome. These are 
just a few examples supporting the use of CXCR3 ligands as biomarkers to optimize individual 
treatment strategies. 
Of note, interpretation of CXCL10 concentrations may be complicated considering recent reports on 
the detection of natural antagonistic forms of CXCL10, as observed in chronically HCV-infected 
patients [269]. Upon HCV infection, plasma CXCL10 is truncated by dipeptidyl peptidase IV 
(DPPIV)/CD26, generating its antagonistic form and thus interfering with its function as a pro-
inflammatory leukocyte chemoattractant [270]. Amino-terminal truncation of the IFN-γ-inducible 
CXCR3 ligands by DPPIV was previously evidenced in vitro and indeed impaired their chemotactic 
activity, whilst retaining angiostatic potential [271]. Discovery of this functional difference between 
intact CXCL10 and its naturally occurring, amino-terminally processed form, challenges the 
significance of total, non-discriminatory CXCL10 concentrations detected in patients. 
5. SUMMARY 
CXCL4, CXCL4L1, CXCL9, CXCL10 and CXCL11 all bind, with varying affinity, to different splice 
variants of the CXCR3 receptor and are therefore collectively referred to as the CXCR3 ligands. Their 
pleiotropic character, regulating both leukocyte migration and angiogenesis, implicates these 
chemokines in a broad spectrum of diseases and their pathogenesis. Consequently, the CXCR3 ligands 
have attracted attention as new therapeutic targets. However, the field is still lacking fundamental 
understanding of some of these chemokines. Ongoing research and clinical trials strive towards a 
better understanding of their basic biology, optimization of drug safety as well as efficacy. In 
conclusion, the CXCR3 ligands and their inhibitors represent a new generation of anti-angiogenic and 
anti-inflammatory strategies. 
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FIGURE LEGENDS 
 
Fig. 1 Receptor binding by the IFN-γ-inducible chemokines, CXCL4 and CXCL4L1 
CXCL4, CXCL4L1, CXCL9, CXCL10 and CXCL11, collectively acknowledged as the CXCR3 
ligands, all bind both receptor splice variants CXCR3A and CXCR3B, whereas only CXCL11 binds 
the more distinctive CXCR3-alt [11-15]. CXCL11 also uniquely shows affinity for atypical chemokine 
receptor (ACKR) 3/CXCR7 [272]. On the other hand, both CXCL4 and CXCL11 bind to 
ACKR1/DARC [273, 274]. To some extent, all CXCR3-binding chemokines also display affinity for 
glycosaminoglycan branches on proteoglycans [16].  
* Binding of CXCL4L1 to DARC has not yet been evaluated. 
  
 
Fig. 2 Amino acid sequence alignment of the mature CXCR3-binding chemokines 
The amino acid sequences of mature CXCL4, CXCL4L1, CXCL9 and CXCL11, without their 
respective signal peptides, were optimally aligned with respect to the mature CXCL10 chemokine. 
Their sequence identity compared to CXCL10 was calculated to give a general impression of the 
sequence homology among the CXCR3-binding chemokines. Mismatched amino acids (AA) are 
marked in grey. Gaps are marked in yellow. The differences between CXCL4 and CXCL4L1 are 
additionally marked in red. 
  
 
Fig. 3 The anti-tumoral activity of CXCR3 ligands 
The CXCR3 ligands affect the tumor environment in various ways. Their anti-tumoral activity is the 
net result of their angiostatic effect, preventing tumor neovascularization (A), of the recruitment of 
pro-inflammatory lymphocytes, promoting tumor immunosurveillance (B), and finally, of their 
lymphangiostatic effect, preventing metastatic escape of tumor cells via the lymphatic vasculature (C) 
[31, 51]. 
 
 Fig. 4 The effect of CXCR3 ligands on tumor invasiveness 
CXCR3 ligands may exert a direct effect on CXCR3-positive tumor cells, the nature of which depends 
on the specific splice variant expressed [59]. In case of CXCR3A expression, these chemokines will 
stimulate not only proliferation, but also migration of the CXCR3A-expressing tumor cells, especially 
to other peripheral sources of CXCR3 ligands, thereby promoting and directing tumor metastasis both 
to draining lymph nodes and distant organs, e.g. lung [275]. 
  
TABLES 
Table 1. Fundamental characteristics of the human CXCR3 ligands 
 
CXCL4 CXCL4L1 CXCL9 CXCL10 CXCL11 
Gene 
(HGNC) 
NM_002619 
4q13.3 
NM_002620 
4q13.3 
NM_002416 
4q21.1 
NM_001565 
4q21.1 
NM_005409 
4q21.1 
Mature protein 70 AA 70 AA 103 AA 77 AA 73 AA 
Producer cells Platelets 
Monocytes 
T cells 
Platelets 
Smooth 
muscle cells 
HMVEC 
Fibroblasts 
Macrophages 
PBMC 
HMVEC 
Fibroblasts 
Monocytes 
T cells 
Keratinocytes 
HMVEC 
Fibroblasts 
Astrocytes 
PBMC 
Inducers Thrombin 
(platelets) 
Phorbol ester  
(T cells) 
Thrombin 
(platelets) 
IFN-γ TNF-α 
(fibroblasts) 
IFN-α, IFN-β, 
IFN-γ 
TNF-α 
(fibroblasts) 
IFN-γ, IFN-β 
Processing 
- protease 
- peptide 
product 
- effect on: 
    chemotaxis 
    angiostasis 
 
N.D. 
CXCL417-70 
 
N.D. 
↑ 
 
N.D. 
. N.D 
 
DPPIV/CD26 
CXCL9 3-103 
 
↓ 
= 
 
DPPIV/CD26 
CXCL10 3-77 
 
↓ 
= 
 
DPPIV/CD26 
CXCL11 3-73 
 
↓ 
= 
Ref [44, 276] [43, 44] [37, 39, 41, 
271] 
[38-40, 271, 
277] 
[12, 39, 41, 
271] 
HGNC = HUGO gene nomenclature committee; AA = amino acids; N.D. = not determined; HMVEC = Human 
microvascular endothelial cell; PBMC = Peripheral blood mononuclear cell; TNF = Tumor necrosis factor; 
DPPIV = Dipeptidyl peptidase IV 
 
  
Table 2. CXCR3 ligands in disease 
Disease CXCR3 ligand expression a Function of CXCR3 ligands 
b 
CANCER   
Carcinoma and 
sarcoma 
↑ / ↓ Recruitment of anti-tumoral lymphocytes via CXCR3A (CXCL9, 
CXCL10, CXCL11) 
Angiostatic (all ligands) and lymphangiostatic (CXCL4, CXCL4L1) 
via CXCR3B 
 ↑ Increased tumor invasiveness via CXCR3A (CXCL4, CXCL10) 
Hematopoietic 
malignancies 
↑ Increased tumor cell dissemination (CXCL9, CXCL10, CXCL11) 
Anti-tumoral activity: tumor tissue necrosis, vascular damage, 
protective immune response (CXCL9, CXCL10) 
 ↓ Tumor suppressor gene (CXCL4) 
INFLAMMATORY DISORDERS 
Arthritis ↑ Synovial inflammation (CXCL4, CXCL9, CXCL10) and vascular 
lesions (CXCL4) 
IBD ↑ Mucosal inflammation (CXCL9, CXCL10, CXCL11) 
Diabetes ↑ T cell islet infiltration (CXCL9, CXCL10) 
Decreased pancreatic beta cell proliferation (CXCL10) 
Correlation to angiogenic complication PDR (CXCL4, CXCL9, 
CXCL10) 
Systemic sclerosis ↑ Fibrotic complications in the skin or lung (CXCL4, CXCL10) 
 ↓ Pulmonary function decline (CXCL11) 
Transplant rejection ↑ Biomarkers predicting allograft failure (CXCL9, CXCL10, CXCL11) 
 N.A. Negative regulation of T cell reactivity (CXCL4) 
MICROBIAL PATHOLOGIES 
Malaria ↑ Positive association with CM occurrence and mortality (CXCL4, 
CXCL9, CXCL10) 
CD8+ recruitment to the brain in murine CM (CXCL9, CXCL10) 
 ↑ Intraerythrocytic parasite-killing (CXCL4) 
AIDS ↑ T cell recruitment and virus propagation (CXCL9, CXCL10, 
CXCL11) 
Stimulated virus replication (CXCL9, CXCL10, CXCL11) 
Inhibited host cell attachment and entry (CXCL4) 
Hepatitis ↑ Lobular inflammation and liver fibrosis (CXCL4, CXCL9, CXCL10, 
CXCL11) 
OTHER   
Atherosclerosis ↑ Lesional T cell infiltration (CXCL9, CXCL10, CXCL11) 
Monocyte recruitment and macrophage polarization (CXCL4) 
Promoted uptake and esterification of oxidized LDL (CXCL4) 
Alzheimer’s disease ↑ Promoted astrocyte aggregation (CXCL10) 
Neurotoxicity (CXCL10) 
Thrombocytopenia N.A. Generation of antibodies against CXCL4/heparin complexes 
IBD = Inflammatory bowel disease; PDR = Proliferative diabetic retinopathy; CM = Cerebral malaria; 
AIDS = Acquired immune deficiency syndrome; N.A. = Not applicable 
a ↑ / ↓ = Upregulated or downregulated CXCR3 ligand expression, respectively, depending on the study 
b For references cfr. citations in text  
Table 3. Anti-tumoral effects of CXCR3 ligands: combination or monotherapies in preclinical models 
Mouse model CXCL4 CXCL4L1 CXCL9 CXCL10 CXCL11 Ref 
B16 melanoma      [278-282] 
Lung adenocarcinoma 
(A11, A549, LLC) 
     [278, 280, 
283-286] 
Colon adenocarcinoma 
(CT26, HCT116) 
     [281, 284, 
286, 287] 
Capan-1 pancreatic 
adenocarcinoma 
     [51] 
Renal cell carcinoma 
(RENCA) 
     [288] 
Breast carcinoma 
(66.1, TA3) 
     [289, 290] 
Ovarian carcinoma 
(SKOV3, ES2) 
     [290, 291] 
Glioma 
(GL261, U87) 
     [292-294] 
Malignant peripheral 
nerve sheath tumor 
     [293, 295] 
Meth A fibrosarcoma      [296] 
Angiosarcoma 
(H5V) 
     [297] 
Burkitt’s lymphoma      [298] 
EL4 lymphoma      [299] 
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